JP Morgan Chase’s Bolt Biotherapeutics BOLT Stock Holding History
Bought
Maintained
Sold
Other funds holding BOLT
SI
VC
TC
BOTOTLSJU
P
LCM
NCNMGF
JP Morgan Chase's BOLT Position: Q2 2026 in Review
JP Morgan Chase held its Bolt Biotherapeutics (BOLT) position steady in Q2 2026 at 42 shares worth $165. The position accounts for ﹤0.01% of the portfolio, ranked #7509.
JP Morgan Chase first reported a position in BOLT in Q1 2021 and has held it in 22 quarters since. The position peaked at $8.26M in Q1 2021. 23 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.
- JP Morgan Chase held 42 shares of Bolt Biotherapeutics worth $165 as of Q2 2026.
- JP Morgan Chase left its Bolt Biotherapeutics share count unchanged in Q2 2026.
- Bolt Biotherapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7509 holding.
- JP Morgan Chase first reported a position in Bolt Biotherapeutics in Q1 2021 and has held it in 22 quarters since.
- JP Morgan Chase's Bolt Biotherapeutics position peaked at $8.26M in Q1 2021.
- 23 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.